These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 15158905)
1. Bioavailability of carbamazepine:beta-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets. Koester LS; Bertuol JB; Groch KR; Xavier CR; Moellerke R; Mayorga P; Dalla Costa T; Bassani VL Eur J Pharm Sci; 2004 Jun; 22(2-3):201-7. PubMed ID: 15158905 [TBL] [Abstract][Full Text] [Related]
2. Mathematical evaluation of in vitro release profiles of hydroxypropylmethylcellulose matrix tablets containing carbamazepine associated to beta-cyclodextrin. Koester LS; Ortega GG; Mayorga P; Bassani VL Eur J Pharm Biopharm; 2004 Jul; 58(1):177-9. PubMed ID: 15207552 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of novel immediate release carbamazepine tablets: complexation with hydroxypropyl-β-cyclodextrin in the presence of HPMC. Kou W; Cai C; Xu S; Wang H; Liu J; Yang D; Zhang T Int J Pharm; 2011 May; 409(1-2):75-80. PubMed ID: 21371541 [TBL] [Abstract][Full Text] [Related]
4. Carbamazepine/betaCD/HPMC solid dispersions. I. Influence of the spray-drying process and betaCD/HPMC on the drug dissolution profile. Koester LS; Mayorga P; Bassani VL Drug Dev Ind Pharm; 2003 Feb; 29(2):139-44. PubMed ID: 12648010 [TBL] [Abstract][Full Text] [Related]
5. Formulation, release characteristics and bioavailability study of oral monolithic matrix tablets containing carbamazepine. Barakat NS; Elbagory IM; Almurshedi AS AAPS PharmSciTech; 2008; 9(3):931-8. PubMed ID: 18686038 [TBL] [Abstract][Full Text] [Related]
6. Formulation, release characteristics and bioavailability of novel monolithic hydroxypropylmethylcellulose matrix tablets containing acetaminophen. Cao QR; Choi YW; Cui JH; Lee BJ J Control Release; 2005 Nov; 108(2-3):351-61. PubMed ID: 16154656 [TBL] [Abstract][Full Text] [Related]
8. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-beta-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. Brewster ME; Anderson WR; Meinsma D; Moreno D; Webb AI; Pablo L; Estes KS; Derendorf H; Bodor N; Sawchuk R; Cheung B; Pop E J Pharm Sci; 1997 Mar; 86(3):335-9. PubMed ID: 9050802 [TBL] [Abstract][Full Text] [Related]
9. Formulation and in vitro/in vivo investigation of carbamazepine controlled-release matrix tablets. Ikinci G; Capan Y; Senel S; Dalkara T; Hincal AA Pharmazie; 1999 Feb; 54(2):139-41. PubMed ID: 10084159 [TBL] [Abstract][Full Text] [Related]
10. Comparative bioavailability study of a conventional and two controlled release oral formulations of Tegretol (carbamazepine)--200 mg. Revankar SN; Bhatt AD; Desai ND; Bolar HV; Sane SP; Tipnis HP J Assoc Physicians India; 1999 Sep; 47(9):886-9. PubMed ID: 10778658 [TBL] [Abstract][Full Text] [Related]
11. Controlled release of nifedipine from mucoadhesive tablets of its inclusion complexes with beta-cyclodextrin. Chowdary KP; Kamalakara RG Pharmazie; 2003 Oct; 58(10):721-4. PubMed ID: 14609284 [TBL] [Abstract][Full Text] [Related]
12. Studies on preparation of carbamazepine (CBZ) supersaturatable self-microemulsifying (S-SMEDDS) formulation and relative bioavailability in beagle dogs. Zhang N; Zhang W; Jin Y; Quan DQ Pharm Dev Technol; 2011 Aug; 16(4):415-21. PubMed ID: 20433250 [TBL] [Abstract][Full Text] [Related]
13. Development and in vivo evaluation of buccal tablets prepared using danazol-sulfobutylether 7 beta-cyclodextrin (SBE 7) complexes. Jain AC; Aungst BJ; Adeyeye MC J Pharm Sci; 2002 Jul; 91(7):1659-68. PubMed ID: 12115827 [TBL] [Abstract][Full Text] [Related]
14. In vitro controlled release of vinpocetine-cyclodextrin-tartaric acid multicomponent complexes from HPMC swellable tablets. Ribeiro L; Ferreira DC; Veiga FJ J Control Release; 2005 Mar; 103(2):325-39. PubMed ID: 15763617 [TBL] [Abstract][Full Text] [Related]
15. Transbuccal tablets of carbamazepine: formulation, release and absorption pattern. Giannola LI; De Caro V; Giandalia G; Siragusa MG; D'Angelo M; Lo Muzio L; Campisi G Int J Immunopathol Pharmacol; 2005; 18(3 Suppl):21-31. PubMed ID: 16848984 [TBL] [Abstract][Full Text] [Related]
16. In vitro/in vivo studies on a buccal bioadhesive tablet formulation of carbamazepine. Ikinci G; Capan Y; Senel S; Alaaddinoğlu E; Dalkara T; Hincal AA Pharmazie; 2000 Oct; 55(10):762-5. PubMed ID: 11082839 [TBL] [Abstract][Full Text] [Related]
17. Effect of SBE7-beta-cyclodextrin complexation on carbamazepine release from sustained release beads. Smith JS; Macrae RJ; Snowden MJ Eur J Pharm Biopharm; 2005 May; 60(1):73-80. PubMed ID: 15848059 [TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of zaleplon complexation with cyclodextrins and hydrophilic polymers in solution and in solid state. Jablan J; Szalontai G; Jug M J Pharm Biomed Anal; 2012 Dec; 71():35-44. PubMed ID: 22898722 [TBL] [Abstract][Full Text] [Related]
19. Discriminatory dissolution method for quality control measurements of carbamazepine immediate release tablets based on in vitro--in vivo investigations. Xu C; Zou M; Wang Y; Liu Y; Yan J; Wu Y; Cheng G Drug Dev Ind Pharm; 2012 Jun; 38(6):679-88. PubMed ID: 21988132 [TBL] [Abstract][Full Text] [Related]
20. Studies on solubility and hypoglycemic activity of gliclazide beta-cyclodextrin-hydroxypropylmethylcellulose complexes. Aggarwal S; Singh PN; Mishra B Pharmazie; 2002 Mar; 57(3):191-3. PubMed ID: 11933849 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]